Eliminate Albumin-associated Risks
Free of albumin from all sources (no BSA, no HSA, no rHSA). It avoids albumin-related batch-to-batch variation, variable molecular structure and potential contamination risks, achieving truly fully defined chemical composition.
Exceptional Batch Consistency
Removal of large-molecule albumin components yields an extremely pure formulation with constant composition across batches. It fundamentally eliminates inter-batch variation and ensures high reproducibility for long-term culture and differentiation workflows.
Empower IND/BLA Submission
Animal-origin-free, human-source-free, albumin-free, with fully defined chemical composition and clear traceable raw material documentation. It significantly reduces the difficulty of CMC regulatory review and shortens the timeline for new drug applications.
| Product Name | Pack Size | Storage | Shelf Life | Cat. No. |
|---|---|---|---|---|
| iPSC Serum-Free Medium Base | 400mL/bottle | 2–8 ℃, protected from light | 12 months | NC0401 |
| Serum-free iPSC Medium Supplement (Albumin-free) | 100mL/bottle | -20 ℃, protected from light | 12 months | NC0403.S |
Product Advantages
High-efficiency expansion: Stable 20–27-fold expansion per passage (96 hours) over 12 consecutive passages, greatly reducing time and material costs in manufacturing.
Sustained pluripotency: Pluripotency markers remain at extremely high levels at P10: TRA-1-60 ≥97%, SSEA4 ≥99%, OCT4 ≥97%, SOX2 ≥98%. Cells exhibit typical morphology with no spontaneous differentiation.
Suspension compatible: Albumin-free formulation delivers clean background, ideal for iPSC-derived exosome preparation and research & production workflows requiring strict elimination of exogenous protein interference.
Performance Data
1.Cell Morphology
2.Cell Expansion Fold
| Passage | Culture Vessel | Seeding Density /cm² | Medium Volume (mL) | Harvested Cell Count | Expansion Fold | Growth Duration (h) |
|---|---|---|---|---|---|---|
| P1 | 6-well plate | 15600 | 2 | 3.59E+06 | 23.95 | 96 |
| P2 | 4.1E+06 | 27.38 | ||||
| P3 | 3.31E+06 | 22.08 | ||||
| P4 | 3.85E+06 | 25.70 | ||||
| P5 | 3.91E+06 | 26.12 | ||||
| P6 | 3.16E+06 | 21.11 | ||||
| P7 | 3.8E+06 | 25.35 | ||||
| P8 | 3.51E+06 | 23.36 | ||||
| P9 | 3.55E+06 | 23.69 | ||||
| P10 | 3.72E+06 | 24.84 | ||||
| P11 | 3.12E+06 | 20.79 | ||||
| P12 | 3.27E+06 | 21.86 |
3.Population Doubling Time & Cumulative Expansion Fold
4.High Expression of Pluripotency Markers
| Group | TRA-1-60 | SSEA4 | OCT4 | SOX2 |
|---|---|---|---|---|
| P10 | 97.71% | 99.97% | 97.74% | 98.96% |
